Low Dose of Midazolam is Superior to Conventional Dose for Rapid Sequence Intubation in Emergency Department (ED)

This study has been completed.
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
First received: October 30, 2008
Last updated: July 25, 2011
Last verified: July 2011
Midazolam has been used in rapid sequence intubation for a long time, and the recommended dose is 0.1mg/kg. In some studies, however, the reduced dose has been used with the concern of hemodynamic instability. We would like to investigate that the low dose midazolam could be used rather than the standard recommended dose, and also compare it to the etomidate, recently used sedatives, with respect to the side effects and the easy performance of intubation.

Condition Intervention
Drug: Low dose midazolam

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Study Start Date: October 2008
Study Completion Date: January 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose midazolam Drug: Low dose midazolam


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients who need rapid sequence intubation in emergency room

Exclusion Criteria:

  • in hypotension(systolic blood pressure less than 90 mmHg
  • severe trauma patients
  • pregnant
  • allergic to midazolam, etomidate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00783731

Korea, Republic of
Seoul National University Bundang Hospital, Emergency room
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Boramae Medical Center
Seoul, Korea, Republic of, 156-707
Sponsors and Collaborators
Seoul National University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00783731     History of Changes
Other Study ID Numbers: RSI study 
Study First Received: October 30, 2008
Last Updated: July 25, 2011
Health Authority: Korea: Food and Drug Administration

Keywords provided by Seoul National University Hospital:

Additional relevant MeSH terms:
Adjuvants, Anesthesia
Anesthetics, General
Anesthetics, Intravenous
Anti-Anxiety Agents
Central Nervous System Agents
Central Nervous System Depressants
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on February 09, 2016